**CLAIMS**

1. Use of a composition comprising genetically unmodified stem cells expressing angiopoietin-1 (Ang1) and vascular endothelial growth factor (VEGF) at a ratio [Ang1:VEGF] between 2:1 and 30:1 in the manufacture of a medicament for treating an inflammatory disorder in a subject, in which administration of the medicament increases production and/or function of anti-inflammatory cells in a subject.

2. Use according to Claim 1, in which the anti-inflammatory cells are Th2 cells, TReg cells or M2-type macrophages.

3. Use according to Claim 1 or 2, in which administration of the medicament increases the number of M2-type macrophages in the subject.

4. Use according to Claim 1, 2 or 3, in which the administration of the medicament increases the number of M2-type macrophages to at least 10% of the total monocyte population in the subject.

5. Use according to any of Claims 1 to 3, in which administration of the medicament increases the number of M2-type macrophages to at least 80% of the total monocyte population in the subject.

6. Use according to any of Claims 2 to 5, in which the M2-type macrophages are CD14++CD16+.

7. Use according to any preceding claim, in which administration of the medicament promotes the polarization of macrophages from an M1 to an M2 phenotype.

8. Use according to any of Claims 1 to 6, in which administration of the medicament promotes the differentiation of pro-inflammatory T helper cells to Th2 or TReg cells.

9. Use according to Claim 8 in which the pro-inflammatory T helper cells are Th17 cells.

10. Use according to any preceding claim, in which the increased production and/or function of anti-inflammatory cells in the subject results in:

- a reduction in IL-6 level in the subject;

- a reduction in TNF-alpha level in the subject; and/or,

- an increase in IL-10 level in the subject.

11. Use according to any of Claims 1 to 9, in which administration of the medicament increases the level of IL-10 in the subject; and/or decreases the levels of any one of IL-6, TNF-alpha and/or IL-17 in the subject.

12. Use according to any preceding claim, in which administration of the medicament also inhibits the production and/or function of pro-inflammatory cells.

13. Use according to Claim 12, in which the pro-inflammatory cells are Th17 cells or M1-type macrophages.

14. Use of a composition comprising genetically unmodified stem cells expressing angiopoietin-1 (Ang1) and vascular endothelial growth factor (VEGF) at a ratio [Ang1:VEGF] between 2:1 and 30:1 in the manufacture of a medicament for treating an inflammatory disease in a subject.

15. Use according to any preceding claim, in which the genetically unmodified stem cells express vascular endothelial growth factor (VEGF) in an amount less than about 0.05 $\mu g/10^6$ cells.

16. Use according to any preceding claim, in which the genetically unmodified stem cells express Ang1:VEGF at a ratio of at least about 20:1.

17. Use according to any preceding claim, in which the genetically unmodified stem cells are mesenchymal precursor cells.

18. Use according to any of Claims 14 to 17, in which the inflammatory disease is diabetes, abnormal wound healing, heart attack, stroke, peripheral vascular disease, amputation, kidney disease, kidney failure, blindness, neuropathy, nephropathy, retinopathy, inflammation, impotence or nonalcoholic steatohepatitis (NASH).

19. Use according to any of Claims 14 to 18, in which the inflammatory disease is type II diabetes.

20. Use according to any preceding claim, in which the medicament is formulated to comprise about 0.1 x $10^6$ to about 3 x $10^6$ stem cells per kg based on the weight of the subject.

21. Use according to any of Claims 18 to 20, in which following administration of the medicament any one of the following indicates that the diabetes or an associated condition or symptom of diabetes has been treated in the subject:

- reduction in HbA1c value (% of total haemoglobin);
- reduction in fasting insulin levels;
- reduction in IL-6 levels;
- reduction in TNF-α levels; and/or
- increase in adiponectin levels.

22. Use according to any of Claims 18 to 21, in which the subjects glucose levels are inadequately controlled by metformin.

23. Use according to any of Claims 18 to 22, in which the subject has a baseline HbA1c value greater than 7.5%.

24. Use according to any of Claims 14 to 17, in which the inflammatory disease is rheumatoid arthritis.

25. Use according to Claim 24, in which following administration of the medicament any one of the following indicates that the rheumatoid arthritis has been treated:

- ACR20;
- ACR50;
- ACR70;
- reduction in IL-6 levels; and/or
- reduction in disease activity score.

26. Use according to any of Claims 14 to 17, in which the inflammatory disease is diabetic nephropathy.

27. Use according to Claim 26, in which following administration of the medicament any one of the following indicates that the diabetic nephropathy has been treated:

- inhibition of decline in eGFR and/or mGFR;

- improvement in eGFR and/or mGFR; and/or

- reduction in IL-6 levels.

28. Use according to Claim 26 or 27, in which the subjects baseline eGFR is greater than about 35 ml/min/1.73m$^2$.

29. Use according to any preceding claim, in which the genetically unmodified stem cells express Ang1:VEGF at a ratio between 5:1 and 20:1.

30. Use according to any preceding claim, in which the genetically unmodified stem cells express Ang1 in an amount between 0.1 μg/10$^6$ cells and 1.0 μg/10$^6$ cells.

31. Use according to any preceding claim, in which the genetically unmodified stem cells express Vascular Endothelial Growth Factor (VEGF) in an amount less than 0.03 μg/10$^6$ cells.